The First Human Has Been Subject to Partial Reprogramming in a Clinical Trial

Imagine telling a tired old eye cell, “Listen, I am not asking you to become a baby cell again. Please do not throw a developmental tantrum. Just remember how to do your job.” That, in plain English, is the ambition behind partial reprogramming. And now, for the first time, that idea has moved from mouse papers, conference buzz, and biotech optimism into a human eye trial.

The trial number is NCT07290244. ClinicalTrials.gov lists it as a first-in-human Phase 1 study of ER-100 in adults with optic nerve conditions: open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, mercifully abbreviated NAION, because biology has a talent for naming things like a committee trapped in an elevator [1]. The study is not designed to prove that ER-100 restores vision. Not yet. Phase 1 is the safety room. The first questions are blunt: can people tolerate a single dose, what side effects appear, and does anything concerning happen over time [1]?

To understand why this matters, rewind to 2006. Shinya Yamanaka and Kazutoshi Takahashi showed that adult mouse cells could be pushed backward into induced pluripotent stem cells, or iPS cells, by adding four genes: Oct3/4, Sox2, Klf4, and c-Myc [2]. A year later, similar work was shown with adult human fibroblasts [3]. This was a jaw-dropper. A mature cell was not as locked into its fate as everyone had assumed. With the right molecular shove, a skin cell could be made stem-cell-like again.

Wonderful. Also terrifying. Because full reprogramming is not a spa day for cells. It is more like wiping the hard drive. A skin cell stops acting like a skin cell. That may be useful in a dish, where scientists want to make stem cells. It is not what you want inside a person’s retina, unless your medical plan is “let us see what happens,” which is generally a poor plan, ranking somewhere below eating gas-station sushi during a heat wave.

Partial reprogramming tries to stop the rewind before the cell loses its identity. The goal is not to turn a retinal neuron into an embryo-like cell. The goal is to nudge an aged or injured cell toward a younger pattern of gene activity while keeping it a retinal neuron. Early mouse work made this idea less ridiculous. In 2016, researchers reported that short, cyclic expression of Yamanaka factors could improve several aging-like features in mice, including a premature-aging model [4]. That was preliminary animal evidence, not a human therapy. But it gave the field a dangerous new sentence: maybe aging biology can be pushed backward without erasing cell identity.

The eye became the proving ground for a good reason. Retinal ganglion cells are neurons in the back of the eye that send visual information to the brain. In glaucoma and NAION, these cells and their long axon cables are damaged. Once they are gone, they are not politely replaced by a fresh batch. Central nervous system neurons are not famous for saying, “No worries, I’ll regenerate.” They are more famous for not doing that.

In 2020, a major study from Lu and colleagues used three factors - Oct4, Sox2, and Klf4, or OSK - in mouse retinal ganglion cells. Notice the missing troublemaker: c-Myc. The study reported that OSK restored more youthful DNA methylation patterns, promoted axon regeneration after injury, and reversed vision loss in mouse models of glaucoma and aging [5]. DNA methylation is one kind of epigenetic mark. Think of DNA as the cookbook and epigenetic marks as sticky notes telling the cell which recipes to use. Same cookbook, different kitchen behavior.

Follow-up mouse work reported that OSK gene therapy could sustain vision recovery in a glaucoma model, including results after two months of OSK expression [6]. Again, mice. Important mice, but mice. The animal-to-human translation gap is not a crack in the sidewalk; it is the Grand Canyon with pipettes.

ER-100 is built on this OSK idea. According to the trial record, participants receive ER-100 as a single treatment, undergo eye and laboratory safety testing, provide samples such as tears and urine, complete quality-of-life questionnaires, and are followed long term [1]. The therapy uses a modified adeno-associated virus, or AAV, to deliver genetic instructions, with doxycycline used to control OSK expression [1]. That control switch is central. In partial reprogramming, dose, timing, tissue targeting, and shutdown are not boring details. They are the difference between “maybe rejuvenation” and “what did we just do?”

This is where David Sinclair’s Information Theory of Aging enters, wearing a lab coat and carrying a software metaphor. The theory argues that aging is driven partly by a loss of youthful epigenetic information - not just broken genes, but disorganized instructions about which genes should be on or off [7]. In this view, the genome is the hardware, the epigenome is the software, and aging is software corruption. You still have the DNA, but the cell increasingly misreads its role.

Sinclair’s group has published mouse data supporting this broad model. In one Cell paper, they argued that DNA repair processes can disturb the epigenome, leading cells to lose aspects of their identity, and that OSK-based reprogramming can reverse some measures of aging in mice [8]. That is the optimistic version: the cell has a backup copy of youthfulness, and OSK knows where the dusty file cabinet is.

Now the annoying but necessary adult supervision: not everyone agrees that the Information Theory of Aging has been proven. Timmons and Brenner published a critique arguing that the theory had not been adequately tested by the available experiments [9]. That disagreement is not a side drama. It is the field being science rather than marketing. The right position is not “this definitely reverses aging” or “this is nonsense.” The right position is the less emotionally satisfying one: partial reprogramming has produced striking animal results, the theory behind it is plausible and debated, and humans are where the fantasy gets audited.

That is why the ER-100 trial matters even if it helps no one’s vision. It is a safety test of a new class of medicine. Gene therapies can have long-lasting effects, so the FDA recommends long-term follow-up for some gene therapy products to watch for delayed adverse events [10]. That may sound bureaucratic. Good. Bureaucracy is annoying until someone injects a gene-regulating therapy into an eye. Then you suddenly become a fan of clipboards.

The money has followed the excitement. Partial reprogramming has gone from an exotic stem-cell concept to a serious rejuvenation technology reviewed in the scientific literature [11]. Public funding is visible too: NIH RePORTER includes projects focused on in vivo epigenetic reprogramming of retinal ganglion cells [12]. And ClinicalTrials.gov now lists an industry-sponsored Phase 1 trial for ER-100 [1]. Funding does not prove truth. It proves that enough people believe the question is worth paying to answer.

So what should a normal reader take from this? First, the clinical trial number is NCT07290244. Second, ER-100 is not an approved treatment and should not be described as proven age reversal. Third, partial reprogramming is a real scientific strategy: briefly and carefully activating factors associated with cellular youth, trying to restore function without erasing identity. Fourth, the eye is a smart first battlefield because it is accessible, measurable, and medically desperate.

The grand dream is not merely better eye drops. It is that damaged cells might contain more recoverable function than we thought. Maybe some old cells are not dead batteries. Maybe some are confused employees with bad instructions, lousy lighting, and a manager named Entropy. The trick is to remind them who they are without making them forget what they are. That is a beautiful idea. It is also a dangerous one. Which is exactly why the first human trials matter.

References

1. ClinicalTrials.gov. Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions). NCT07290244.

2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676.

3. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-872.

4. Ocampo A, Reddy P, Martinez-Redondo P, et al. In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. Cell. 2016;167(7):1719-1733.e12.

5. Lu Y, Brommer B, Tian X, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588(7836):124-129.

6. Karg MM, Lu YR, Refaian N, et al. Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma. Cell Reprogram. 2023;25(6):288-299.

7. Lu YR, Tian X, Sinclair DA. The Information Theory of Aging. Nat Aging. 2023;3(12):1486-1499.

8. Yang JH, Hayano M, Griffin PT, et al. Loss of epigenetic information as a cause of mammalian aging. Cell. 2023;186(2):305-326.e27.

9. Timmons JA, Brenner C. The information theory of aging has not been tested. Cell. 2024;187(5):1101-1102.

10. U.S. Food and Drug Administration. Long Term Follow-up After Administration of Human Gene Therapy Products: Guidance for Industry. January 2020.

11. Paine PT, Nguyen A, Ocampo A. Partial cellular reprogramming: A deep dive into an emerging rejuvenation technology. Aging Cell. 2024;23(2):e14039.

12. NIH RePORTER. In vivo epigenetic reprogramming of retinal ganglion cells. Project details.